5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      BACTEROIDES FRAGILIS TOXIN COORDINATES A PRO-CARCINOGENIC INFLAMMATORY CASCADE VIA TARGETING OF COLONIC EPITHELIAL CELLS

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Pro-carcinogenic bacteria have the potential to initiate and/or promote colon cancer, in part via immune mechanisms that are incompletely understood. Using Apc Min mice colonized with the human pathobiont enterotoxigenic Bacteroides fragilis (ETBF) as a model of microbial-induced colon tumorigenesis, we show that the Bacteroides fragilis toxin (BFT) triggers a pro-carcinogenic multi-step inflammatory cascade requiring IL-17R, NF-κB, and Stat3 signaling in colonic epithelial cells (CECs). Although necessary, Stat3 activation in CECs is not sufficient to trigger ETBF colon tumorigenesis. Notably, IL-17-dependent NF-κB activation in CECs induces a proximal to distal mucosal gradient of C-X-C chemokines, including CXCL1 that mediates the recruitment of CXCR2-expressing polymorphonuclear immature myeloid cells with parallel onset of ETBF-mediated distal colon tumorigenesis. Thus, BFT induces a procarcinogenic signaling relay from the CEC to a mucosal Th17 response that results in NFκB activation selectively in distal colon CECs, that collectively triggers myeloid cell-dependent distal colon tumorigenesis.

          Related collections

          Author and article information

          Journal
          101302316
          33345
          Cell Host Microbe
          Cell Host Microbe
          Cell host & microbe
          1931-3128
          1934-6069
          13 April 2018
          01 February 2018
          14 February 2018
          16 May 2018
          : 23
          : 2
          : 203-214.e5
          Affiliations
          [1 ]Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD-21287, USA
          [2 ]Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD-21287, USA
          [3 ]Translational Tissue Engineering Center, Wilmer Eye Institute and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21287, USA
          [4 ]Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
          [5 ]Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
          [6 ]Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD-21287, USA
          [7 ]Department of Pathology, Radboud University Medical Centre, Geert Grooteplein-Zuid 10, 6525 GA, Nijmegen, Netherlands
          [8 ]Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD-21287, USA
          [9 ]Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD-21287, USA
          Author notes
          [* ]correspondence: fhousse1@ 123456jhmi.edu (F.H) or csears@ 123456jhmi.edu (C.L.S.)
          [10]

          these authors contributed equally to the study

          [11]

          Lead contact

          [&]

          deceased

          [#]

          Current addresses: Erik Thiele Orberg, Department of Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany; Abby L. Geis, Department of Microbiology & Immunology, Arkansas College of Osteopathic Medicine, Fort Smith, AR 72916, USA; Christine M. Dejea, Center for Drug Evaluation and Research, Food Drug Administration, Silver Spring, MD 20993; Florencia McAllister, Department of Clinical Cancer Prevention. The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Elizabeth C. Wick, Department of Surgery, University of California San Francisco, San Francisco, CA 94143; Payam Fathi, Vanderbilt University School of Medicine, Nashville, TN 37232

          Article
          PMC5954996 PMC5954996 5954996 nihpa958779
          10.1016/j.chom.2018.01.007
          5954996
          29398651
          1f1f68bc-8c9d-47ea-b506-0c9dc94b5e8b
          History
          Categories
          Article

          Comments

          Comment on this article